Dexcom Clarity and G7 CGM

Dexcom, Inc. is a biosensing company founded in 1999 whose press releases are datelined San Diego. Its stated mission is to empower people to take control of health through biosensing technology, and it sells continuous glucose monitors for all types of diabetes.

The Dexcom G7 and G7 15 Day send glucose readings in real time to a phone or receiver, and the Stelo biosensor is an over-the-counter option for adults not on insulin. Clinics use Dexcom Clarity to review shared patient data, including remotely, with working with all Dexcom CGM systems, plus a developer portal for integration partners.

• Real-time CGM: G7 sends glucose readings to a phone or receiver.
• 15-day wear: G7 15 Day offers up to 15.5 days of wear.
• Clarity for clinics: trend reports, daily and overlay views, AGP and time-in-range statistics.
• Over-the-counter option: Stelo biosensor for adults 18 and older not on insulin.
• Automated insulin delivery: the G7 15 Day integrates with automated insulin delivery systems.
• Developer portal: connected-partner ecosystem and API access.

Endocrinology clinics reviewing patients' glucose reports remotely between visits. Distributors and pharmacy chains in Vietnam bundling CGM with clinic follow-up programs. Hospital diabetes centers integrating glucose data into their own systems through the developer portal.

Clinics can review patients' shared glucose data in Clarity for telehealth or in-person visits. Registration for Clarity is free, according to the provider page. The G7 15 Day offers up to 15.5 days of wear with a reported MARD of 8%, a company figure. Sharing is automatic once linked through the phone app.

CGM use is expanding from insulin users to type 2 diabetes and preventive care, with Dexcom presenting outcomes data at ATTD and ADA in 2026. International revenue grew 26% in Q1 2026, including USD 213.4 million through distributors, which shows regional distributors are a main route. Vietnam and Southeast Asia have rising diabetes prevalence and growing interest in CGM at endocrinology clinics.

Dexcom, Inc. was founded in 1999 per its website and reported Q1 2026 revenue of USD 1.192 billion. It sells through distributors and a Distributors Portal; international revenue was USD 359.6 million in Q1 2026. Health Canada authorized the G7 15 Day on 2026-07-13.